VHA -FUNDING FOR SITE COORDINATION OF COVID-19 CLINICAL TRIALS

Document text

Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2024
Award: $85,255
Funding agency: National Institute of Allergy and Infectious Diseases

This interagency agreement leverages the research capabilities, expertise, and interests of NIAID and the Veterans Health Administration (VHA) to respond to the current COVID-19 pandemic.  Under this IAA, VHA research sites will participate in the ACTIV umbrella clinical research studies on candidate medical countermeasures against COVID-19 and other respiratory viral illnesses, including candidate monoclonal antibodies, antiviral drugs, immunomodulators, and other new or repurposed investigational drugs with differing mechanisms of action.

Terms: <Agreement><Airway infections><Anti-viral Agents><COVID crisis><COVID epidemic><COVID infected patient><COVID pandemic><COVID patient><COVID positive patient><COVID-19><COVID-19 crisis><COVID-19 epidemic><COVID-19 era><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infected patient><COVID-19 pandemic><COVID-19 patient><COVID-19 period><COVID-19 positive patient><COVID-19 public health crisis><COVID-19 years><COVID19 patient><COVID19 positive patient><CV-19><Clinical Research><Clinical Study><Clinical Treatment Moab><Clinical Trials><Coronavirus Infectious Disease 2019><Emergencies><Emergency Situation><Evaluation><Funding><Immunomodulators><Infrastructure><Inpatients><Investigational Drugs><Investigational New Drugs><Monoclonal Antibodies><NIAID><National Institute of Allergy and Infectious Disease><Research><Respiratory Infections><Respiratory Tract Infections><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infected patient><SARS-CoV-2 pandemic><SARS-CoV-2 patient><SARS-CoV-2 positive patient><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Site><Therapeutic><Vaccination><Veterans Health Administration><Veterans Health Affairs><Viral><anti-viral compound><anti-viral drugs><anti-viral medication><anti-viral therapeutic><anti-virals><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infected patient><coronavirus disease 2019 pandemic><coronavirus disease 2019 patient><coronavirus disease 2019 positive patient><coronavirus disease 2019 public health crisis><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease infected patient><coronavirus disease pandemic><coronavirus disease patient><coronavirus disease positive patient><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 patient><coronavirus infectious disease-19><coronavirus patient><immune modulators><interest><mAbs><medical countermeasure><monoclonal Abs><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><point of care><research study><respiratory><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 positive patient>